H1975 Gefitinib-Resistant EGFR T790M NSCLC Model Service

The H1975 Gefitinib-Resistant EGFR T790M NSCLC Model Service provides an in vivo arena for the gatekeeper-mutation era of lung cancer: a tumor whose EGFR carries both the sensitizing L858R lesion and the T790M gatekeeper substitution grows straight through first-generation inhibitor therapy, making it the definitive substrate for benchmarking mutant-selective next-generation agents and rational combinations. Alfa Cytology supports this program with sequence-verified H1975 banks, documented refractoriness baselines, validated subcutaneous xenograft procedures, and endpoint analysis that captures both the T790M lesion itself and the constitutive MET co-activation that shapes this line's biology — delivering cohorts whose resistance is molecularly real and interpretable.

Overview of H1975 Gefitinib-Resistant EGFR T790M NSCLC Model

When gefitinib and erlotinib — the first-generation, reversible EGFR tyrosine kinase inhibitors — entered the clinic in the early 2000s, they produced striking regressions in EGFR-mutant lung cancer, yet relapse followed within about a year in most patients. In roughly half of those progressions, sequencing of resistant tumors uncovered a second-site substitution at threonine 790 of the EGFR kinase domain: the T790M gatekeeper mutation. H1975, a lung adenocarcinoma line carrying both L858R and T790M on the same allele together with mutant p53, stands as this era's reference standard — approximately one hundred-fold less sensitive to gefitinib than L858R-only lines, and effectively unresponsive in vivo to first-generation inhibitor dosing.

Fig 1. In vivo efficacy in the H1975 gefitinib-resistant xenograft model — gross tumors, 21-day tumor growth curves and weights under CyH, gefitinib and combination, with HE/p-EGFR/EGFR/PD-L1/Ki-67 immunohistochemistry confirming EGFR pathway and PD-L1 suppression by the combination. (Zhang, Guihong, et al., 2024)

The mechanism proved subtler than mere steric blocking of the drug pocket. Biochemical and crystallographic work demonstrated that T790M's dominant effect is to raise the kinase's affinity for ATP by more than an order of magnitude, restoring ATP binding to wild-type levels and thereby closing the therapeutic window that sensitizing mutations had opened — a drug must now outcompete far more intracellular ATP to engage its target. H1975's resistance biology carries additional texture: the line co-expresses a constitutively active MET receptor — without genomic amplification — that engages in collaborative cross-activation with mutant EGFR, anticipating the MET-driven bypass resistance found in about 20 percent of clinical first-generation TKI failures. Two construction routes serve the model. The constitutive route implants native H1975, whose tumors grow indifferently through gefitinib, allowing mutant-selective inhibitors to be graded against a refractory baseline — rociletinib-class third-generation agents have produced outright regressions in this setting where erlotinib is powerless. The acquired route derives gefitinib-conditioned derivatives, exemplified by the characterized H1975/GR line, in which intermittent drug exposure selects further refractoriness accompanied by epithelial–mesenchymal transition. Together these platforms powered the preclinical case for third-generation TKI development and remain the standard testbed for combinations targeting EGFR, MET, and ERBB3 dependence in T790M-positive disease.

Principles of H1975 Gefitinib-Resistant EGFR T790M NSCLC Model Construction

The model's logic rests on a precisely defined molecular lesion rather than on selection pressure alone. Because H1975 already carries T790M in cis with L858R, every tumor cell begins the experiment refractory to first-generation inhibitors, and the experimental question becomes one of comparative efficacy: which agent or combination can control a tumor that gefitinib cannot. Where investigators instead wish to model the clinical trajectory of therapy-conditioned resistance, intermittent in vitro gefitinib exposure generates acquired derivatives with further diminished sensitivity and mesenchymal features. Across both routes, three anchors discipline the study: sequence-verified genotype, a quantified refractoriness baseline, and endpoint analysis that interrogates both the gatekeeper lesion and the line's constitutive MET co-activation.

Our Services

Alfa Cytology operates this model as a refractory-baseline business: H1975 banks are sequence-verified for the L858R/T790M genotype and benchmarked for gefitinib insensitivity before inoculation, xenografts are established under standardized Matrigel-assisted procedures, and endpoint panels interrogate both the gatekeeper lesion and MET co-activation — so the refractoriness your candidates must overcome is confirmed, quantified, and mechanistically annotated.

Workflow of H1975 Gefitinib-Resistant EGFR T790M NSCLC Model Construction

Working with a constitutively resistant line compresses the construction timeline — the genotype does the resisting — but demands the same rigor in verification, dosing, and endpoint interpretation. The sequence below traces a typical engagement from bank verification to refractory cohorts with full molecular annotation.

1. Study design and route selection: The plan fixes the route — native constitutive H1975 or an acquired gefitinib-conditioned derivative — along with group sizes, oral dosing schedules, vehicle controls, and the quantitative tumor-growth-inhibition criteria that will define meaningful efficacy.
2. Cell authentication and baseline profiling: H1975 banks are STR-authenticated and mycoplasma-cleared, the L858R/T790M cis configuration is reconfirmed by sequencing, baseline gefitinib IC50 values are documented, and MET expression status is recorded before study entry.
3. Acquired-resistance derivation (where selected): For the acquired route, cells are exposed intermittently to escalating gefitinib concentrations over weeks to months until a stable derivative emerges, with IC50 shifts, E-cadherin/vimentin expression, and morphology documented along the way.
4. Host preparation and tumor inoculation: Female NCr nu/nu or BALB/c nude mice are randomized and implanted subcutaneously with a standardized inoculum — classically 1 × 10⁷ cells in 50% Matrigel — and tumors are grown to the pre-specified starting volume.
5. Oral gefitinib dosing and refractory-tumor surveillance: Gefitinib dosing begins at treatment initiation and continues uninterrupted; tumor dimensions are captured on a fixed schedule, refractoriness is quantified as tumor-growth inhibition relative to vehicle, and breakthrough kinetics are archived.
6. Endpoint characterization: Tumors are excised and profiled by H&E with p-EGFR, p-AKT, p-ERK and Ki-67 immunostaining, MET status assessment, and sensitive detection of T790M — with C797S screening added for third-generation-era studies.
7. Data integration and reporting: Tumor-growth kinetics, inhibition ratios, and molecular annotations are consolidated — with constitutive-versus-acquired comparisons highlighted where both routes are run — into the final study report.

Fig 2. H1975 Gefitinib-Resistant EGFR T790M NSCLC Model Construction Workflow.

Case Study-H1975 Gefitinib-Resistant EGFR T790M NSCLC Model Development

Alfa Cytology has conducted H1975 gefitinib-resistance studies within preclinical programs addressing T790M-positive disease, including mutant-selective inhibitor benchmarking and MET-inclusive combination strategies. Engagements of this scope have covered sequence-verified bank preparation, Matrigel-assisted xenograft establishment, uninterrupted oral gefitinib dosing with scheduled tumor measurement, and terminal immunohistochemical and molecular profiling — producing tumor-growth, inhibition-ratio and lesion-annotation datasets used for internal decision-making. Further detail can be provided upon request as your program matures.

Why Choose Alfa Cytology?

A constitutively resistant model is only trustworthy if its genotype is verified and its refractoriness is quantified before dosing begins. Alfa Cytology makes both conditions of entry, then adds the MET-aware endpoint analysis this line's biology demands.

• STR-authenticated H1975 banks with sequencing-confirmed L858R/T790M cis genotype.
• Documented gefitinib IC50 baselines for every bank entering in vivo work.
• Both routes available: native constitutive refractoriness and acquired H1975/GR-type derivatives.
• Standardized Matrigel-assisted subcutaneous procedures with high, reproducible take rates.
• Endpoint panels spanning p-EGFR, p-AKT, p-ERK, Ki-67, MET status, and T790M/C797S allele detection.
• Strictly preclinical operations — research-stage programs receive our complete attention.
• Integrated reporting that pairs growth kinetics with lesion and pathway annotation in one package.

Contact Us

If your pipeline targets T790M-positive disease — through mutant-selective inhibitors, MET combinations, or antibody strategies — reach out to us to scope an H1975 gefitinib-resistant study matched to your mechanism and endpoints. Contact Alfa Cytology today, and our team will return a tailored proposal with cohort designs and projected timelines.

For research use only. Not intended for any clinical use.